⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALVO News
Alvotech Ordinary Shares
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
globenewswire.com
ALVO
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
globenewswire.com
ALVO
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
globenewswire.com
ALVO
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
globenewswire.com
ALVO